Abbott/$ABT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abbott
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Ticker
$ABT
Sector
Primary listing
NYSE
Employees
114,000
Headquarters
Website
Abbott Metrics
BasicAdvanced
$233B
16.78
$7.97
0.70
$2.32
1.76%
Price and volume
Market cap
$233B
Beta
0.7
52-week high
$141.23
52-week low
$110.86
Average daily volume
5.3M
Dividend rate
$2.32
Financial strength
Current ratio
1.821
Quick ratio
1.135
Long term debt to equity
25.503
Total debt to equity
27.087
Dividend payout ratio (TTM)
28.42%
Interest coverage (TTM)
15.68%
Profitability
EBITDA (TTM)
11,453
Gross margin (TTM)
56.17%
Net profit margin (TTM)
32.43%
Operating margin (TTM)
18.97%
Effective tax rate (TTM)
-76.99%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
6.62%
Return on equity (TTM)
30.93%
Valuation
Price to earnings (TTM)
16.776
Price to revenue (TTM)
5.396
Price to book
4.77
Price to tangible book (TTM)
11.25
Price to free cash flow (TTM)
34.343
Free cash flow yield (TTM)
2.91%
Free cash flow per share (TTM)
3.894
Dividend yield (TTM)
1.73%
Forward dividend yield
1.76%
Growth
Revenue change (TTM)
5.85%
Earnings per share change (TTM)
151.50%
3-year revenue growth (CAGR)
-1.82%
10-year revenue growth (CAGR)
7.72%
3-year earnings per share growth (CAGR)
18.50%
10-year earnings per share growth (CAGR)
10.35%
3-year dividend per share growth (CAGR)
7.64%
10-year dividend per share growth (CAGR)
9.46%
What the Analysts think about Abbott
Analyst ratings (Buy, Hold, Sell) for Abbott stock.
Bulls say / Bears say
Abbott exceeded Wall Street’s Q2 profit expectations, posting adjusted EPS of $1.26 compared to the $1.25 consensus, thanks to strong medical device demand and $5.37 billion in device sales beating forecasts (Reuters)
Sales of continuous glucose monitors jumped 21.4% year-over-year to $1.9 billion in Q2, driving a 13.4% increase in the Medical Devices segment and underscoring the Diabetes Care division’s momentum (Reuters)
Management reiterated its full-year 2025 guidance, projecting organic sales growth of 7.5%–8.5% and adjusted EPS of $5.05–$5.25, reflecting confidence in Abbott’s diverse business portfolio (Barron's)
Pre-market shares dropped about 5% after Q2 results, as Abbott provided a Q3 profit forecast of $1.28–$1.32 per share, below the $1.34 analysts expected (Reuters)
The Diagnostics segment is still underperforming, with sales declining due to fading COVID-19 testing demand and continued challenges from China’s volume-based procurement policies (Barron's)
Abbott is facing over 700 federal lawsuits combined in multidistrict litigation, alleging its preterm baby formulas cause necrotizing enterocolitis, creating a risk of large financial penalties (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Abbott Financial Performance
Revenues and expenses
Abbott Earnings Performance
Company profitability
Abbott News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abbott stock?
Abbott (ABT) has a market cap of $233B as of September 14, 2025.
What is the P/E ratio for Abbott stock?
The price to earnings (P/E) ratio for Abbott (ABT) stock is 16.78 as of September 14, 2025.
Does Abbott stock pay dividends?
Yes, the Abbott (ABT) stock pays dividends to shareholders. As of September 14, 2025, the dividend rate is $2.32 and the yield is 1.76%. Abbott has a payout ratio of 28.42% on a trailing twelve-month basis.
When is the next Abbott dividend payment date?
The next Abbott (ABT) dividend payment date is unconfirmed.
What is the beta indicator for Abbott?
Abbott (ABT) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.